Regeneron Pharmaceuticals Inc. (REGN)

• Annual Data
• Quarterly Data

Regeneron Pharmaceuticals Inc., Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity

		Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Accounts payable
	Accrued payroll and related costs
	Accrued clinical trial expense
	Accrued sales-related charges, deductions, and royalties
	Income taxes payable
	Other accrued expenses and liabilities
	Accrued expenses and other current liabilities
	Capital and facility lease obligations, current portion
	Deferred revenue from Sanofi, current portion
	Deferred revenue, other, current portion
	Convertible senior notes, current portion
	Other current liabilities
	Current liabilities
	Capital and facility lease obligations, excluding current portion
	Deferred revenue from Sanofi
	Deferred revenue, other
	Convertible senior notes, excluding current portion
	Other noncurrent liabilities
	Noncurrent liabilities
	Total liabilities
	Preferred Stock, $.01 par value; issued and outstanding - none
	Class A Stock, convertible, $.001 par value
	Common Stock, $.001 par value
	Additional paid-in capital
	Retained earnings
	Accumulated other comprehensive income (loss)
	Treasury Stock, at cost
	Stockholders’ equity
	Total liabilities and stockholders’ equity

Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).